Literature DB >> 3007340

Rearrangement of 21-hydroxylase genes in disease-associated MHC supratypes.

M J Garlepp, A N Wilton, R L Dawkins, P C White.   

Abstract

Human cDNA probes for 21-hydroxylase (21-OH) and for complement component C4 are used on restriction digests of the members of several families with interesting supratypes. The presence of two Taq I fragments of 3.7 kb and 3.2 kb in size with a 21-OH probe is confirmed in most individuals who show no evidence of C4 deletions or 21-OH deficiency. Most individuals also show a doublet of weakly hybridizing bands at approximately 2.5 kb, the smaller of which is part of the 21 A gene. The arrangement of the 21-OH genes on disease-associated supratypes was examined, and it is shown that copies of the same supratype from unrelated individuals are usually identical. Evidence is provided for deletions of 21A on the B8, C4AQ0, C4B1, BfS, DR3 and B18, C4A3, C4BQ0, BfF1, DR3 supratypes and a duplication of 21A on the B14, C4A2, C4B1/B2, BfS supratype. Gene rearrangements may be relevant to diseases such as juvenile onset diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007340     DOI: 10.1007/bf00377968

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  16 in total

1.  Genetic control of suppressor lymphocyte function in myasthenia gravis: relationship of impaired suppressor function to HLA-B8/DRW3 and cold reactive lymphocytotoxic antibodies.

Authors:  P J Zilko; R L Dawkins; K Holmes; C Witt
Journal:  Clin Immunol Immunopathol       Date:  1979-10

2.  Detection of specific sequences among DNA fragments separated by gel electrophoresis.

Authors:  E M Southern
Journal:  J Mol Biol       Date:  1975-11-05       Impact factor: 5.469

Review 3.  Molecular genetics of the fourth component of human complement and steroid 21-hydroxylase.

Authors:  M C Carroll; K T Belt; A Palsdottir; Y Yu
Journal:  Immunol Rev       Date:  1985-10       Impact factor: 12.988

4.  The coexistence of IgA deficiency and 21-hydroxylase deficiency marked by specific MHC supratypes.

Authors:  T J Cobain; M S Stuckey; J McCluskey; A N Wilton; A Gedeon; M J Garlepp; F T Christiansen; R L Dawkins
Journal:  Ann N Y Acad Sci       Date:  1985       Impact factor: 5.691

5.  Disease associations with complotypes, supratypes and haplotypes.

Authors:  R L Dawkins; F T Christiansen; P H Kay; M Garlepp; J McCluskey; P N Hollingsworth; P J Zilko
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

6.  The structural basis of the multiple forms of human complement component C4.

Authors:  K T Belt; M C Carroll; R R Porter
Journal:  Cell       Date:  1984-04       Impact factor: 41.582

7.  Complement allotyping in SLE: association with C4A null.

Authors:  F T Christiansen; R L Dawkins; G Uko; J McCluskey; P H Kay; P J Zilko
Journal:  Aust N Z J Med       Date:  1983-10

8.  Mapping of steroid 21-hydroxylase genes adjacent to complement component C4 genes in HLA, the major histocompatibility complex in man.

Authors:  M C Carroll; R D Campbell; R R Porter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

9.  Family studies of IgA deficiency.

Authors:  A N Wilton; T J Cobain; R L Dawkins
Journal:  Immunogenetics       Date:  1985       Impact factor: 2.846

10.  Genetic polymorphism in human glycine-rich beta-glycoprotein.

Authors:  C A Alper; T Boenisch; L Watson
Journal:  J Exp Med       Date:  1972-01       Impact factor: 14.307

View more
  31 in total

1.  The genomic structure of two ancestral haplotypes carrying C4A duplications.

Authors:  K Tokunaga; W J Zhang; F T Christiansen; R L Dawkins
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

2.  Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency.

Authors:  E Mornet; P Crété; F Kuttenn; M C Raux-Demay; J Boué; P C White; A Boué
Journal:  Am J Hum Genet       Date:  1991-01       Impact factor: 11.025

3.  Prenatal DNA analysis in four embryos/fetuses at risk of 21-hydroxylase deficiency.

Authors:  T Matsumoto; T Kondoh; T Kamei; M Yoshimoto; Y Tsuji; K Suzumori; R Izumi; N Iwatani; N Niikawa
Journal:  Eur J Pediatr       Date:  1988-12       Impact factor: 3.183

Review 4.  The Gordon Wilson Lecture. Congenital adrenal hyperplasia.

Authors:  M I New
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

5.  Rearrangements and point mutations of P450c21 genes are distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia.

Authors:  Y Morel; J André; B Uring-Lambert; G Hauptmann; H Bétuel; M Tossi; M G Forest; M David; J Bertrand; W L Miller
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

6.  Quantitative variation of C4 variant proteins associated with many MHC haplotypes.

Authors:  L Truedsson; Z Awdeh; E J Yunis; S Mrose; B Moore; C A Alper
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

7.  Class III gene rearrangements in Thai/Chinese supratypes containing null or defective C4 alleles.

Authors:  P H Kay; E Martin; R L Dawkins; P Charoenwong
Journal:  Immunogenetics       Date:  1988       Impact factor: 2.846

8.  21-hydroxylase deficiency families with HLA identical affected and unaffected sibs.

Authors:  P J Sinnott; P A Dyer; D A Price; R Harris; T Strachan
Journal:  J Med Genet       Date:  1989-01       Impact factor: 6.318

9.  The "Sardinian" HLA-A30,B18,DR3,DQw2 haplotype constantly lacks the 21-OHA and C4B genes. Is it an ancestral haplotype without duplication?

Authors:  L Contu; C Carcassi; J Dausset
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

10.  Unusual clustering of diseases in a Canadian Old Colony (Chortitza) Mennonite kindred and community.

Authors:  M A Jaworski; J D Slater; A Severini; K R Hennig; G Mansour; J G Mehta; R Jeske; J Schlaut; C Y Pak; J W Yoon
Journal:  CMAJ       Date:  1988-06-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.